<DOC>
	<DOCNO>NCT01698281</DOCNO>
	<brief_summary>This therapeutic exploratory Phase 2 study evaluate AEZS-108 compare standard single agent cytotoxic chemotherapy ( SSCC ) measure median time progression-free survival ( PFS ) patient chemotherapy refractory triple negative ( ER/PR/HER2-negative ) LHRH-R positive metastatic breast cancer .</brief_summary>
	<brief_title>Phase 2 Trial AEZS-108 Chemotherapy Refractory Triple Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Women ≥ 18 year age 2 . Histologically document breast cancer ( either primary metastatic site ) ( ) ERnegative ( 0 ) , ( ii ) PRnegative ( 0 ) , ( iii ) HER2negative , define IHC ( immunohistochemistry ; IHC 0/1 , nonoverexpressing ) FISH ( fluorescence situ hybridization ; FISH negative ) CISH ( chromogen situ hybridization ; CISH negative ) . 3 . Expression LHRH receptor confirm IHC archival ( current biopsy breast tumor metastatic site ) breast cancer tissue 4 . Progressive disease failure 1 3 prior chemotherapy regimens recurrent metastatic ( Stage IV ) disease ( prior adjuvant/neoadjuvant therapy allow ) 5 . Measurable disease RECIST 1.1 criterion ; least one target lesion previously irradiate . 1 . Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 2 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia recent myocardial infarction ( within 6 month enrollment ) 3 . Leptomeningeal disease brain metastasis require steroid therapeutic intervention 4 . Left ventricular ejection fraction ( LVEF ) &lt; 50 % , determine echocardiogram MUGA scan 5 . Compromised organ marrow function evidence follow : thrombocyte count : &lt; 100x109/L absolute neutrophil count ( ANC ) : &lt; 1.5x109/L hemoglobin : &lt; 6.0 mmol/L ( &lt; 9 g/100 mL ) AS ( A ) T , AL ( A ) T : &gt; 2.5 time upper limit normal range ( ULN ) ( &gt; 5x ULN clearly relate liver metastasis ) bilirubin : &gt; 1.5 mg/dL creatinine : &gt; 1.5 mg/dL creatinine clearance &lt; 40 mL/min . 6 . Systemic anticancer therapy radiotherapy within 21 calendar day first dose study drug* ) * also exclude patient anticipated ongoing concomitant anticancer therapy study 7 . Prior exposure anthracyclines anthracenediones treatment metastatic breast cancer include liposomal doxorubicin ( Doxil ) , doxorubicin , daunorubicin , mitoxantrone 8 . Prior adjuvant anthracyclines cumulative anthracycline dose ≥ 300 mg/m2 9 . Ongoing therapeutic anticoagulation 10 . Patients surgically sterile postmenopausal must agree use duration study reliable method birth control define : complete abstinence intrauterine device ( IUD ) publish data show low expected failure rate &lt; 1 % per year , method publish data show low expected failure rate le 1 % per year 11 . Investigational therapy within 30 calendar day first schedule day protocol treatment ( investigational therapy define treatment currently regulatory authority approve indication ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>